BioCentury
ARTICLE | Clinical News

NuCana reports Phase Ib data for Acelarin in first-line biliary cancer

January 26, 2018 8:16 AM UTC

NuCana plc (NASDAQ:NCNA) reported interim data from the Phase Ib ABC-08 trial showing that Acelarin (NUC-1031) plus cisplatin as first-line treatment led to an objective response rate (ORR) of 50% in eight evaluable patients with advanced biliary tract cancer. Data were presented at the American Society of Clinical Oncology Gastrointestinal Cancer Symposium in San Francisco.

This year, NuCana plans to start a Phase III trial of Acelarin in the first-line biliary tract cancer indication. The product is a modified version of gemcitabine that uses ProTide technology from Morvus Technology Ltd. (Llanvetherine, U.K.)...